Browsing: Astellas Pharma Inc.

SHANGHAI and SUZHOU, China and TOKYO, Dec. 28, 2023 /PRNewswire/ — Elpiscience Biopharma, Ltd. (Chairman and CEO: Darren Ji, MD, Ph.D., “Elpiscience”) and…

– Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel…

– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly doubled…

First-in-class treatment option reduces number and intensity of hot flashes and night sweats  TOKYO, Dec. 10, 2023 /PRNewswire/ — Astellas…

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy*…

– Accelerating the development of the life science ecosystem centered on Tsukuba — Promoting innovative drug discovery research using AI…

Key study results include: IZERVAY dosed EM through 2 years demonstrated a statistically significant year-over-year reduction of 14% in the…

– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –– Enfortumab…

Data include three late-breaking abstracts, underscoring Astellas’ efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO, Oct.…